Debu Tripathy, MD, chair, Breast Medical Oncology, University of Texas MD Anderson Cancer Center, discusses the potential for immunotherapy in the treatment of HER2+ breast cancer.
Roundtable Roundup: Adjuvant Therapy for HR+, HER2- Breast Cancer
June 17th 2025In separate, live virtual events, William J. Gradishar, MD; and Tiffany A. Traina, MD, discussed multiple scenarios for a patient with hormone receptor–positive, HER2-negative breast cancer to potentially receive hormonal plus endocrine therapy.
Read More